( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (	0112669192 0112675011	(₩)	Oesic-usc.	)
Gg/เอเอเลียส์	) 0112698507 . 0112694033		எனது இல	)
Telephone	) 0112675449 . 0112675280		Mv No	)DDG/PHS-1/NSACP/2011
'n			1353.52031.556	2
77,000	) 0112693866	[[[[[[] [[] [[] [[] [] [] [] [] [] [] []		
Qualint	) 0112693869	The state of the s	හිබෙල-නය්	)
Fax	)0112692913		உமது இல	)
			Your No"	)
විදාහ නැසැල	)postmaster@health.gov.lk			
மின்னஞ்சல் முகவாி	)	* 0.88 mace		
e-mail	)	සුවසිරිපාය	र्देशस्य	)
		சுவசிரிபாய	திகதி	)
පේ <b>නි</b> අඛචිය	) www.health.gov.lk		District	0803.2017
இணையத்தளம்	)	SUWASIRIPAYA	Date	) *03.2017
mahaita	Y .			

eසூவிக, පෝෂණ සහ දේශීය වෛදා අමාත ශය சுகாதார,போசணைமற்றும் சுதேசவைத்தியஅமைச்சு Ministry of Health, Nutrition& Indigenous Medicine

General Circular No. 01 - 19/2017

All Provincial / Regional Directors of Health Services,

All Directors of Teaching Hospitals,


All Heads of Specialized Campaigns,

All Heads of Government Medical Institutions.

# Management of healthcare workers following occupational exposure to blood and other body fluids and post exposure prophylaxis for HIV

- A). The General Circular letter reference No-36/2001 dated 12th March 2001 on "Management of Health-Care Worker Exposures to HIV and Recommendations for Post Exposure Prophylaxis" is hereby cancelled.
- B). This circular outlines recommendations for the management of health care workers who experience occupational exposures to blood and other body fluids that might contain Human Immunodeficiency Virus (HIV).
- C). Although preventing exposures to blood and other body fluids that might contain HIV is the primary means of preventing occupationally acquired HIV infection, appropriate post-exposure management is an important element of workplace safety. Department of Health has considered information available worldwide and recommends that the following procedure for post exposure prophylaxis (PEP) be followed in an accidental exposure. This circular recommends all health care workers with occupational exposures to HIV to attend to a STD clinic with the source blood sample as early as possible for management and follow up.
- D). It is the responsibility of the head of the institution to make sure
  - 1. That there is a functional system of management of healthcare workers following occupational exposure to blood and other body fluids.
  - 2. That antiretroviral drugs (ARV) are available for PEP.

### E). Management of occupational exposures



<sup>\*</sup>Starter Pack -Antiretroviral medication for the post exposure prophylaxis for 5 days. We recommend keeping this starter pack in a readily accessible place / places such as OPD / ETU / ICU / PCU / Pharmacy.

# F). Definition of a Health Care Worker (HCW) for the purpose of this circular

The term HCW refers to all persons working in the health care setting who has the potential for exposures to infectious materials, including body substances (e.g. blood, tissue and specific body fluids), contaminated medical supplies and equipment, and contaminated environmental surfaces(1).

### G). Definition of Exposure

An "exposure" that may place a health care worker at risk for HIV infection and requires consideration of PEP is defined as follows:

### 1. Type of Exposure

- i. Percutaneous injury Needle stick or cut with a sharp object.
- ii. Contact of mucous membranes
- iii. Non-intact skin- chapped, abraded or afflicted with dermatitis

### 2. Type of body fluid

With blood, tissue or other body fluids that are potentially infected.

(Semen, vaginal secretions, breast milk, cerebrospinal fluid (CSF), synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid and amniotic fluid are considered potentially infectious)(2).

Saliva, urine, nasal secretions, vomitus and feces bear no risk of HIV infection in the absence of visible blood. Exposure to tears and sweat does not require post exposure prophylaxis (2)(3).

# H). Risk of Occupational Transmission of HIV to HCWs from HIV infected blood

•	Percutaneous injury	0.30%	95% CI = 0.2% - 0.5%.(1)(3)(5)	
•	Mucous membrane	0.09%	95% CI = 0.006% - 0.5%.(1)(3)	8
				i i

# I). Management of the Exposed Site

Exposed sites should be cleansed of contaminated fluid as soon as possible after exposure. Wounds and skin sites are best cleansed with soap and water, avoiding irritation of the skin. Exposed mucous membranes should be flushed with water. Alcohol, hydrogen peroxide,

betadine or other chemical cleansers are best avoided. HCWs should be made aware to avoid "milking" or squeezing out needle-stick injuries or wounds (AII)(2)(3).

# J). Evaluating the Exposure

- I. Prompt initiation of PEP is recommended for exposure to blood, visibly bloody fluids or other potentially infectious material from HIV-infected or HIV-unknown sources in any of the significant exposure situations outlined in Table 1(AII).
- II. Whenever a worker has been exposed to potentially HIV-infected blood, visibly bloody fluids or other potentially infectious material through the percutaneous or muco-cutaneous routes or through non-intact skin, PEP is indicated. For these exposures, prompt initiation of PEP followed by telephone or in-person consultation with a clinician experienced in HIV PEP is recommended.

# Table 1: Exposures requiring initiation of starter Pack

- Break in the skin by a sharp object (including hollow-bore, solid-bore, and cutting needles or broken glassware) that is contaminated with blood, visibly bloody fluid, or other potentially infectious material, or that has been in the source patient's blood vessel.
- Bitten by a person with visible bleeding in the mouth that causes break in the skin or mucosa of the exposed worker.
- Splash of blood, visibly bloody fluid or other potentially infectious material to a mucosal surface (mouth, nose, or eyes).
- A non-intact skin (e.g.: dermatitis, chapped skin, abrasion or open wound) exposure to blood, visibly bloody fluid or other potentially infectious material

# K). Determine the HIV status of the source patient and initiation of PEP

# a. Known Positive patient

Start PEP immediately with available three drug regimen.

Contact Consultant Venereologist (STD clinic) as early as possible.

b. Sero-status is unknown

# I. When source patient is available

Consent for HIV testing of the source patient should be sought (AII) (2). If facilities are available, rapid HIV test on source sample should be carried out. This can be done at closest STD clinic or any other lab where rapid test is available.

### II. Consent for HIV testing

- When the source patient has the capacity to consent to HIV testing, informed consent is required.
- When the source person does not have the capacity to consent, consent may be
  obtained from a surrogate, or anonymous testing may be done if a surrogate is not
  immediately available (2).
- If the result from testing source patient is not immediately available, considering severity of exposure and epidemiological likelihood of HIV status of the source, starter pack can be initiated (preferably within 2 hours of the exposure) while source testing and further evaluation are underway (2).
- III. When source patient is not available (e.g. needles in sharp bins and laundry)
  Considering severity of exposure and epidemiologic likelihood of HIV exposure, starter pack can be initiated. Decision regarding continuation of PEP where source patient is not available should be made on a case by case basis by Venereologist / MO-STD.

# L). Timing of the Initiation of PEP

- i. When a potential occupational exposure to HIV occurs, every effort should be made to initiate PEP as soon as possible, ideally within 2 hours (AII). A first dose of PEP should be offered to the exposed worker while the evaluation is underway (2).
- ii. Decisions regarding initiation of PEP beyond 72 hours post exposure should be made on a case-by-case basis with the understanding of diminished efficacy when timing of initiation is prolonged (AIII)(2).

# M). Recommended PEP regimen

Three drug regimen

TDF 300mg daily

FTC 200mg daily

LPV/r 400/100mg 12 hourly or ATV/r 300/100mg daily

Venereologist could decide on alternative regimens according to circumstances.

# N). Duration of PEP Regimen

PEP need to be considered for 28 days (1)(2)(3).

When the source patient is confirmed to be HTV-negative, PEP could be discontinued(1)(3).

- 0). Baseline testing for the exposed health care worker and Follow up
- i. Confidential baseline HIV testing of the exposed worker should be obtained at the time the occupational exposure is reported or within 3 days of the exposure (AIII).
- ii. All exposed workers receiving PEP should be re-evaluated within 3 days of the exposure. This allows for further clarification of the nature of the exposure, review of available source patient data and evaluation of adherence to and toxicities associated with the PEP regimen (1)(3).
- iii. The exposed worker should be evaluated weekly while receiving PEP to assess treatment adherence, side effects of treatment, interval physical complaints and emotional status.
- iv. Clinicians should provide risk-reduction counseling to HIV-exposed workers to prevent secondary transmission during the 16-week follow-up period. HIV-exposed workers should be educated and counseled on:
  - I . Use of condoms to prevent potential sexual transmission.
  - II. Avoiding pregnancy and Brest feeding (2).
  - III. Avoiding needle shearing.
  - IV. Refraining from donating blood, plasma, organs, tissue or semen.
  - V. identifying symptoms of primary HIV infection and report as soon as possible.

Inves	tigations reco	mmended for	the health	ncare worker v	vho are on	PEP	i -
	Baseline	Week 1	Week 2	Week 3	Week 4	Week 10	Week
Clinic visit	<b>~</b>	✓ Or by telephone	<b>✓</b>	√ Or by telephone	<b>✓</b>		
Pregnancy Test	~						
FBC */LFT and RFT	<b>V</b>		<b>Y</b>		~		
HIV Test	· /	(Marie 1971)				<b>✓</b>	<b>√</b>

<sup>\*</sup>Follow-up FBC is indicated only for those receiving a Zidovudine-containing regime.

Week 10, 16 HIV testing should be done by using ELISA

HIV testing recommended for the healthcare worker who are not on PEP at baseline, week 6 and 12 from the exposure date.

- P). Exposed workers who are pregnant and breast feeding
- 1. Pregnancy and breast feeding are not contraindications for PEP and recommended regimens can be used (2).
- 2. Before administering PEP to a pregnant woman, the clinician should discuss the potential benefits and risks to her and to the fetus (2)(3).
- 3. Clinicians should counsel women who may have been exposed to HIV through occupational exposure to avoid breastfeeding for 3 months after the exposure (AII). If HIV infection is definitively excluded in the source patient at any time prior to 3 months post-exposure, the woman may resume breastfeeding.

### Q). Exposure Report

If an occupational exposure occurs, the circumstances and post exposure management should be recorded in the HCW's confidential exposure report (Annex I).

#### R). References

- U S Public health service guideline. Updated US Public Health Service Guideline for Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendation for Post exposure Prophylaxis. Infection Control and Hospital Epidemiology. 2013;34:875-892
- New York State Department of Health AIDS Institute. HIV prophylaxis following occupational exposure. www.hivguidelines.org. Updated October 2014. Accessed April 2016
- iii. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of healthcare worker exposures to HIV and recommendations for post exposure prophylaxis.2013.
- iv. World Health Organization. Guidelines on post exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV related infections among adults, adolescents and children: recommendations for public health approach. December 2014 supplement to the 2013 guidelines.
- v. UK guidelines for the use of HIV post-exposure prophylaxis following sexual exposure. 2015.
- vi. AIDS EAGO. HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers' expert Advisory Group on AIDS (2008)2008.

#### S). Level of evidence

- A High quality evidence
- B Moderate quality evidence
- C Low quality evidence
- D Very low quality evidence

Dr. J.M.W. Jayasundara Bandara

Director General of Health Services (Actg.) W. Jayasundara Bandara
Director General of Health Services (Acting)
Ministry of Health, Nutrition & Indigenous Medicine,
No. 385, "Suwasiripaya",

://	2. Institut	tion	3. Name / Designation of HCW
4. Date / Time of Exp	osure	5.Details of the p	rocedure
J		i. Laboratory /The Others ii. How the expos	
6. Details of the exposi	ure	- 341	
Type of body fluid:		Amount: Sm	all /Large
. Percutaneous injury -	- Yes / No		
i. Mucosal exposure : `	Yes / No		
If Yes, Site of expos		40 T	* E
5	Yes / No		
ii. Non – intact skin : Y	Yes / No		
ii. Non – intact skin : Y	Ycs / No		
ii. Non – intact skin : Y  Details of the source  Source ident	ified: Yes / No  If Already A  Stage of the Recent Vira  CD4 Cell C  On ART	HIV Positive e diseasel Load	esART Regimen
ii. Non – intact skin : Y  Details of the source  Source ident	ified: Yes / No  If Already A  Stage of the Recent Vira  CD4 Cell C  On ART  Resistance I	HIV Positive e disease I Load ount Yes / No If Y	esART Regimen
ii. Non – intact skin : Y  Details of the source  Source ident	If Already A - Stage of the - Recent Vira - CD4 Cell C - On ART Resistance I If HIV status t - Rapid Test	HIV Positive e disease l Load ount Yes / No If Y	esART Regimen

8.Management of post exposure	
PEP recommended Y	es / No
PEP accepted by HCW	es / No
<ul> <li>If Yes ART Regimen</li> </ul>	
Tres AKT Regimen	
9. Follow up HIV Test on HCW	10. Name, Signature and Designation of Counselor

12 / 16 Weeks: Positive / Negative